According to a recent LinkedIn post from Cooler Heads, the company is drawing attention to a patient testimonial describing the use of its Amma scalp cooling device during chemotherapy. The patient reportedly retained 95–99% of her hair, and the post underscores the perceived impact of hair preservation on the overall treatment experience.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also reiterates that Amma is an FDA‑cleared scalp cooling device aimed at minimizing hair loss in adult cancer patients undergoing treatment for solid tumors. For investors, the emphasis on real‑world patient outcomes and regulatory clearance may signal Cooler Heads’ efforts to differentiate its technology in the oncology supportive‑care market.
This type of patient‑focused evidence could support adoption by cancer centers and infusion clinics if corroborated at scale, potentially expanding the company’s addressable market. It may also strengthen Cooler Heads’ positioning versus competing scalp cooling solutions, which could be relevant to future revenue growth, reimbursement discussions, and partnership opportunities with providers or payers.